Shop by goal

Popular compounds

GHK-Cu

GLP1-RC-RT

Research resources

Ipamorelin vs Tesamorelin

Q: What is the difference between Ipamorelin and Tesamorelin?

Ipamorelin is a Growth Hormone Secretagogue compound (Subcutaneous route) - Selective growth hormone secretagogue. Short half-life; published protocols typically use pulsatile evening administration. Tesamorelin is a Growth Hormone Secretagogue compound (Subcutaneous route) - Stabilised GHRH analog approved for HIV-associated lipodystrophy. Once-daily SC dosing.

Q: Which has a longer half-life, Ipamorelin or Tesamorelin?

Ipamorelin has the longest published plasma half-life (2 h), compared with Tesamorelin (~24 min).

Q: How often is each compound dosed in the research literature?

Ipamorelin: once daily at a published dose range of 0.2–0.3 mg; Tesamorelin: once daily at a published dose range of 1–2 mg. These are descriptive reference parameters, not dosing recommendations.

Q: Can you buy Ipamorelin and Tesamorelin for research use?

Yes - Ipamorelin, Tesamorelin are available from New-U Research Compounds as lab-verified (>99% HPLC) compounds.

Published pharmacokinetic and receptor-characteristic comparison with primary-source references.

Updated August 2026 Research use only

IPAMORELIN

Ipamorelin

Growth Hormone Secretagogue

TESAMORELIN

Tesamorelin

Growth Hormone Secretagogue

Key research differences

Ipamorelin Tesamorelin Receptor profile Growth Hormone Secretagogue Growth Hormone Secretagogue Development status Research peptide Research peptide Published half-life 2 h ~24 min Research distinction Selective growth hormone secretagogue. Short half-life; published protocols typically use pulsatile evening administration Stabilised GHRH analog approved for HIV-associated lipodystrophy. Once-daily SC dosing

Published research parameters

Ipamorelin NNC 26-0161 View Ipamorelin → Tesamorelin Egrifta View Tesamorelin → Receptor profile Growth Hormone Secretagogue Growth Hormone Secretagogue Class Growth Hormone Secretagogue Growth Hormone Secretagogue Plasma half-life 2 h ~24 min Time to Cmax ~30 min ~15 min Development status Research peptide Research peptide Study context Educational estimate Regulatory label PK Primary publications Raun K et al., Eur J Endocrinol 139:552 (1998) FDA Egrifta (tesamorelin) USPI (2022) Summary Selective growth hormone secretagogue. Short half-life; published protocols typically use pulsatile evening administration. Stabilised GHRH analog approved for HIV-associated lipodystrophy. Once-daily SC dosing.

View published study parameters

Ipamorelin NNC 26-0161 View Ipamorelin → Tesamorelin Egrifta View Tesamorelin → Route in published studies Subcutaneous Subcutaneous Published study interval Once daily Once daily Published dose range 0.2–0.3 mg 1–2 mg Published study regimen No published study ladder No published study ladder

Source references

Raun K et al.

1998

Raun K et al., Eur J Endocrinol 139:552 (1998)

FDA Egrifta (tesamorelin) USPI

FDA prescribing information · 2022

FDA Egrifta (tesamorelin) USPI (2022)

Frequently asked questions

What is the difference between Ipamorelin and Tesamorelin?

Which has a longer half-life, Ipamorelin or Tesamorelin?

How often is each compound dosed in the research literature?

Can you buy Ipamorelin and Tesamorelin for research use?

Continue research

← Compare other compounds

PRECISION. PURITY. PERFORMANCE.

Research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical & Freedom Diagnostics, with Certificates of Analysis published per released batch. Supplied strictly for laboratory research use.

Shop

All research compounds

Price list

Where to buy peptides

Research